New blood test could help flag risk of condition that leads to liver failure, cancer
Globally, about 1.43 million deaths were linked to liver cirrhosis in 2021.
A new blood test called CIRRHOClear, developed by Singapore-based biotech firm Mirxes and the National Cancer Centre Singapore (NCCS), can identify the risk of liver cirrhosis before symptoms develop, potentially minimizing the risk of liver failure and liver cancer. The non-invasive test measures specific microRNA biomarkers in a standard blood sample, providing a high, intermediate or low risk classification for the condition.
In clinical validation studies, CIRRHOClear accurately determined liver cirrhosis risk in 89% of cases and correctly identified those without the condition 95% of the time. Early detection through CIRRHOClear could allow doctors to manage the condition better, potentially slowing its progression and mitigating symptoms. Liver cirrhosis, caused by chronic liver damage from conditions like fatty liver disease, chronic hepatitis or alcohol-related liver disease, is a serious medical situation that can lead to liver failure and hepatocellular carcinoma, the most common form of liver cancer.
Currently, detecting liver cirrhosis in its early stages is challenging, with routine blood tests and ultrasound lacking sensitivity. CIRRHOClear aims to address this issue by providing a practical risk-stratification tool for primary care providers, transforming liver care from reactive treatment to proactive prevention. The test, which involves drawing a small amount of blood, will be available at clinics and screening centers starting October 16, 2023, with plans to introduce the product in other countries.
Written by urgent.news from Straits Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
